Compare Abeona Therapeutics Inc (ABEO) vs iShares Silver Trust (SLV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares Silver Trust — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while iShares Silver Trust trades at $52.99. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.
| ABEO | SLV | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | — |
52-Week High | $7.23 | $105.57 |
52-Week Low | $4.17 | $33.00 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SLV, the iShares Silver Trust ETF, trades at $54.46, down 1.02% on the day, reflecting ongoing volatility in silver prices. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. Recent news highlights silver's 50% decline from January peaks but potential for a rebound amid industrial demand and inflation hedging. Financial ratios are not applicable as this is a commodity ETF tracking physical silver.
The outlook for SLV hinges on silver's dual role as an industrial metal and inflation hedge, with risks including Federal Reserve policy shifts and geopolitical tensions. Analysts see potential for price recovery if macroeconomic conditions support precious metals, but near-term volatility remains high due to rate hike expectations and dollar strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
